Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) has a poor prognosis and limited treatment options.
• There is an urgent need for novel therapeutic strategies against liver cancer.

Purpose of the Study:

• To investigate the antitumor activity and molecular mechanisms of the novel Na+/K+-ATPase inhibitor RX108 in human HCC.
• To evaluate RX108's potential as a targeted therapy for HCC.

Main Methods:

• In vitro studies using human HCC cell lines (Huh7, Hep3B).
• In vivo studies using a human HCC xenograft mouse model.
• Analysis of molecular mechanisms including transporter expression, metabolite levels, and cellular energy metabolism.

Main Results:

• RX108 inhibited HCC cell proliferation and tumor growth in a dose-dependent manner, inducing apoptosis.
• RX108 downregulated alanine serine cysteine transporter 2 (ASCT2) expression, reducing glutamine and glutamate levels.
• RX108 decreased cellular energy metabolism and glutamine transport, indicating glutamine addiction in HCC cells.

Conclusions:

• RX108 demonstrates significant antitumor activity against HCC by targeting glutamine metabolism via Na+/K+-ATPase inhibition.
• Elevated ASCT2 expression in HCC correlates with poor survival, suggesting RX108 as a potential therapy for ASCT2-high HCC.
• RX108 is a promising candidate for clinical development in HCC treatment.